Recent Updates
Recently added Catalysts

LHT344

Phase 1

Healthy | Small molecule | Other |Novartis AG|Last Updated: Jan 13, 2011

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment12
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00414778Safety and Pharmacokinetics of LHT344 in Chinese Healthy SubjectsPHASE1 COMPLETED 12Oct 1, 2006 -Jan 13, 20111 China
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Pharmacokinetics of single and repeat daily oral dose of LHT344 in Chinese healthy subjects
Secondary Endpoints
Safety of single and repeat daily oral dose of LHT344 in Chinese healthy subjects
Unlock Study Endpoints
Study Design & Arms
AllocationNON_RANDOMIZED
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Interventions
NameTypeDescription
LHT344DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — 45 Years
SexALL
Healthy VolunteersYes
Study Sites1

Inclusion Criteria: * Healthy, non-smoking, male or female subjects age 18 to 45 years of age * In good health as confirmed by past medical history, physical examination, electrocardiogram, laboratory tests and urinalysis on the screening and baseline evaluation * Body mass index within the range o...

Countries:China
Unlock Eligibility Criteria